News Search Results
Jun 11, 2026, 13:02 ET HelloNation Explains Why More Kenosha Patients Are Choosing Proactive Eye Treatment With Insights From Eye Care Experts Dr. Sanka and Dr. Singh
explains that many individuals are moving away from the traditional approach of waiting until symptoms become severe before pursuing care. Advances in ophthalmology now allow doctors to identify and manage eye conditions much earlier, often before major vision loss occurs. According to the article, proactive
More news about: HelloNation
Jun 11, 2026, 10:30 ET As celebrations of the 250th Anniversary of the Signing of the Declaration Independence approaches on July 4, Prevent Blindness Issues Warning on the Potential Dangers of Fireworks
Thomas L. Steinemann, MD, Cornea and External Eye Disease, Cataract and Lens Implant Surgery, Metro Health Eye Clinic, and Professor of Ophthalmology at
More news about: Prevent Blindness
Jun 11, 2026, 07:00 ET ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
[email protected] for the pressFrank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Jun 11, 2026, 07:00 ET ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
[email protected] for the pressFrank SmithHead of Global Communications Ophthalmology, Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
More news about: Carl Zeiss Meditec AG
Jun 11, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
ocular surgery. We are confident this step further strengthens our commitment and relationship with Samil and its status of being a leader in ophthalmology." said Erick Co, President and CEO of Formosa Pharmaceuticals."Following our exclusive license agreement signed in January 2026 for the commercialization
More news about: Formosa Pharmaceuticals Inc.,
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche
Jun 09, 2026, 09:10 ET Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Jun 09, 2026, 08:08 ET Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye
moderate-to-severe dry eye disease," said Sandeep Jain, MD, founder and Chief Executive Officer of Selagine Plasma and B.A. Field Professor of Ophthalmology at the University of Illinois Chicago. "The opportunity is not simply to create another tear substitute. The opportunity is to build a standardized,
More news about: Selagine, Inc.
Jun 08, 2026, 16:10 ET Visage Highlights One Platform AI-Optimized at SIIM26
solution in Enterprise Imaging. With Visage 7, customers can display, distribute and manage all Radiology, Breast Imaging, Cardiology, Pathology, Ophthalmology, Dental, OB US, POCUS, Visible Light Photos, Video, and PDFs, regardless of the size of the studies, with the ability to support orders and encounters-based
More news about: Visage Imaging, Inc.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American
More news about: Innovent Biologics
Jun 04, 2026, 16:03 ET B. Riley Securities to Host Mind, Muscle & Vision Healthcare Summit on July 16, 2026
award-winning equity research team, ensuring investors access to differentiated opportunities across psychiatry, neurology, neuromuscular, cardiology, and ophthalmology – many poised for meaningful commercial, clinical trial, and regulatory catalysts into 2027.The summit will feature research analyst-hosted
More news about: B. Riley Securities
Jun 04, 2026, 11:59 ET Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche
Jun 04, 2026, 11:33 ET Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals
More news about: Roche
Jun 04, 2026, 06:00 ET Leading Vision Insurance Plans (2026): VSP Vision Care Ranked Leading Provider for Exams and Eyewear by Consumer365
https://www.cdc.gov/vision-health/about-eye-disorders/why-eye-exams-are-important.html2 American Academy of Ophthalmology, "Your Eyes Could Be Windows to Your Health." Available at:
More news about: Consumer365.org
Jun 04, 2026, 04:35 ET World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the international multi-center Phase 3 clinical study (G-HOPE-001, NCT06238843) of arcotatug tavatecan
More news about: Innovent Biologics
Jun 02, 2026, 14:05 ET ZEISS PiWeb Updates Help Manufacturers Reduce Quality Silos and Scale with Confidence
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Jun 02, 2026, 09:00 ET Luminopia Announces First International Licensing Agreement with ROHTO Pharmaceutical to Launch Pediatric Amblyopia Treatment in Japan
results were published in Ophthalmology, leading to the initial FDA approval for patients aged 4 to 7 years. Based on the robust real-world evidence collected through the PUPiL Registry,
More news about: Luminopia
Jun 02, 2026, 07:00 ET Tavo Biotherapeutics Announces $17 Million Series A Financing to Advance Novel Therapies in Glaucoma and Retinal Disease
development experience will be invaluable as we advance our pipeline.""Tavo has built a compelling pipeline addressing major unmet needs in ophthalmology with differentiated science and a clear clinical development strategy," said Dominik Escher. "We believe these programs have the potential to bring
More news about: Tavo Biotherapeutics
Jun 01, 2026, 16:15 ET Keenova Champions Men's Health Month with Education and Outreach
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
Jun 01, 2026, 12:30 ET Parker Waichman LLP Files Lawsuit on behalf of Pennsylvania Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
remyelination PKM2 modulation offers a potential new paradigm for treating large, underserved, and high-value indications in neurology, ophthalmology, and immunology NEW HAVEN, Conn., June 1, 2026 /PRNewswire/
More news about: Biohaven Ltd.
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announces updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced the preliminary results from a PoC clinical study of its global first-in-class PD-1/IL-2α-bias
More news about: Innovent Biologics
May 28, 2026, 21:02 ET HMS Vision Inc. and Wenzhou Medical University Announce the Expansion of Their Simulation-Based Training Center During Vision China 2026
Wenzhou Medical University, Zhongshan Ophthalmic Center at Sun Yat-sen University, and He Eye Specialist Hospital, HMS Vision supports innovation in ophthalmology and helps reduce preventable blindness across China. Beijing HMS Vision Technical Consulting Co. Ltd. deploys the HelpMeSee Simulation-based Eye
More news about: HMS Vision Inc.